Human Coagulation Factor Viii

Summary

Human Coagulation Factor Viii (CHEMBL2108175) is an approved unknown; indicated across 4 conditions including von willebrand disease (hereditary or acquired) and hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108175
Name	Human Coagulation Factor Viii
Type	Unknown
Max phase	4

Also known as: Antihemophilic factor, Antihemophilic factor (human), Antihemophilic factor human, Antihemophilic factor viii human, human, Antihemophilic human plasma, Factor viii (antihaemophilic factor), Factor viii (human), Factor viii, Factorate, Hemofil m, Human coagulation factor viii

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
von Willebrand disease (hereditary or acquired)	4	MONDO:0024574	Orphanet:903
hemophilia A	4	MONDO:0010602	MONDO:0010602

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2/PHASE3	3
PHASE4	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00243386	PHASE4	COMPLETED	Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00289536	PHASE4	COMPLETED	Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT07416526	PHASE3	RECRUITING	A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NCT00157040	PHASE2/PHASE3	COMPLETED	Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
NCT00157053	PHASE2/PHASE3	COMPLETED	Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157105	PHASE2/PHASE3	COMPLETED	Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
NCT00952822	PHASE1	COMPLETED	Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).